Histogen Inc. (NASDAQ: HSTO – Get a rating) benefited from significant growth in short-term interest during the month of March. As of March 31, there was short interest totaling 470,000 shares, an 82.5% growth from the total of 257,600 shares as of March 15. Based on an average daily trading volume of 1,040,000 shares, the day-to-cover ratio is currently 0.5 days.
Hedge funds have recently increased or reduced their holdings in the stock. Goldman Sachs Group Inc. acquired a new stake in Histogen during the second quarter worth approximately $34,000. Two Sigma Securities LLC increased its stake in Histogen by 124.7% during the third quarter. Two Sigma Securities LLC now owns 52,289 shares of the company worth $40,000 after purchasing an additional 29,019 shares during the period. Millennium Management LLC increased its stake in Histogen by 265.7% during the second quarter. Millennium Management LLC now owns 71,398 shares of the company worth $78,000 after purchasing an additional 51,876 shares during the period. Citadel Advisors LLC increased its stake in Histogen by 29.2% during the second quarter. Citadel Advisors LLC now owns 94,950 shares of the company worth $103,000 after purchasing an additional 21,471 shares during the period. Finally, Geode Capital Management LLC increased its stake in Histogen by 20.0% during the third quarter. Geode Capital Management LLC now owns 207,892 shares of the company worth $157,000 after purchasing an additional 34,649 shares during the period. 6.51% of the shares are currently held by institutional investors and hedge funds.
Shares of NASDAQ: HSTO traded down $0.14 in the midday session on Friday, reaching $0.25. The company’s stock had a trading volume of 17,422,297 shares, compared to an average trading volume of 6,979,450. The stock has a market capitalization of $12.33 million, a price-earnings ratio of -0, 62 and a beta of 0.86. The stock’s 50-day simple moving average is $0.25 and its 200-day simple moving average is $0.41. Histogen has a fifty-two-week low of $0.20 and a fifty-two-week high of $1.23.
Several brokerages have recently released reports on HSTO. Zacks Investment Research upgraded Histogen from a “sell” to a “hold” rating in a Wednesday, January 12 research report. HC Wainwright lowered its price target on Histogen from $2.40 to $1.50 and set a “buy” rating on the stock in a Tuesday, March 29 research report.
About Histogen (Get a rating)
Histogen Inc, a clinical-stage therapeutics company, is focused on developing a proprietary technology platform of hypoxia-generated growth factors and non-stem cell biologics. It offers HST-003, a human extracellular matrix, which is in a Phase 1/2 clinical trial to treat knee articular cartilage defects; HST-004, a cellular conditioned medium solution to treat intervertebral disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19.
Get news and reviews for Histogen Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Histogen and related companies with MarketBeat.com’s free daily email newsletter.